Modeling the impact of peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin therapy on life expectancy and medical care costs in chronic hepatitis C.

被引：0
|
作者：
Jensen, CDM
Bernstein, DE
Hassanein, TI
Foster, GR
Lee, SS
Cheinquer, H
Craxi, A
Cooksley, WGE
Klaskala, W
Green, J
机构：
[1] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
[2] N Shore Univ Hosp, Manhasset, NY USA
[3] Univ Calif San Diego, San Diego, CA 92103 USA
[4] Univ London Imperial Coll Sci Technol & Med, London, England
[5] Univ Calgary, Calgary, AB, Canada
[6] Univ Fed Rio Grande Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil
[7] Inst Clin Med Policlin, Palermo, Italy
[8] Royal Brisbane Hosp, Brisbane, Qld 4029, Australia
[9] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1761
引用
收藏
页码：603A / 603A
页数：1
相关论文
共 50 条
  • [41] Treatment of patients with chronic hepatitis C and normal alanine aminotransferase levels with peginterferon alfa-2a (40 KD) (Pegasys®) and ribavirin.
    Zeuzem, S
    Diago-Madrid, M
    Shiffman, ML
    Reindollar, RW
    Pockros, PJ
    Gane, E
    Tran, A
    Farci, P
    Lamour, F
    HEPATOLOGY, 2002, 36 (04) : 583A - 583A
  • [42] Better safety and quality of life in patients with chronic hepatitis B than in patients with chronic hepatitis C when treated with peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy
    Marcellin, P
    Lau, G
    Piratvisuth, T
    Luo, KX
    Bonino, F
    Thongasawat, S
    Cooksley, G
    Hadziyannis, S
    Chutaputti, A
    Lu, ZM
    Fried, M
    Chow, WC
    Yurdaydin, C
    Berg, T
    Pluck, N
    HEPATOLOGY, 2004, 40 (04) : 668A - 668A
  • [43] Safety and adherence to peginterferon alfa-2a (40KD) plus ribavirin (RBV) in black Americans with chronic hepatitis C (CHC) HCV genotype 1
    Howell, CD
    Jeffers, LS
    Hu, S
    Lopez-Talavera, JC
    GASTROENTEROLOGY, 2004, 126 (04) : A722 - A723
  • [44] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C - Reply
    Fried, MW
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (03): : 260 - 260
  • [45] Peginterferon alfa-2a (40KD) (PEGASYS®) in combination with ribavirin in African American and Caucasian patients with chronic hepatitis CHCV genotype 1:: Safety and tolerability.
    Howell, C
    Jeffers, LS
    Cassidy, W
    Reddy, R
    Sheridan, S
    Ho, I
    Khouri, S
    Harb, G
    HEPATOLOGY, 2003, 38 (04) : 319A - 319A
  • [46] Efficacy and tolerability of peginterferon alfa-2a (40kd) and ribavirin in genotype 4 patients with chronic hepatitis C (CHC) under real life conditions
    Zehnter, E.
    Mauss, S.
    Kaiser, S.
    Boeker, K.
    Lutz, T.
    Heyne, R.
    John, C.
    Moog, G.
    Schober, A.
    Pfaff, R.
    Zipf, A.
    Racky, S.
    Lohmeyer, J.
    Bokemeyer, B.
    Kallinowski, B.
    Witthoeft, T.
    Alshuth, U.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S316 - S316
  • [47] International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2a (40KD) (pegasys®) and ribavirin (copegus®).
    Zuezem, S
    Diago, M
    Gane, E
    Reddy, R
    Pockros, P
    Farci, P
    Gitlin, N
    Lamour, F
    Lardelli, P
    Shiffman, M
    HEPATOLOGY, 2003, 38 (04) : 208A - 208A
  • [48] Population pharmacokinetics of single- or multiple-dose ribavirin (Copegus®) administered with or without peginterferon alfa-2a (40KD) (Pegasys®) in chronic hepatitis c (CHC) patients
    Wade, Janet
    Snoeck, Eric
    Lamb, Matthew
    Duff, Frank
    Wang, Karen
    Grippo, Joseph
    Jorga, Karin
    GASTROENTEROLOGY, 2006, 130 (04) : A838 - A838
  • [49] A comparison of cost-effectiveness of peginterferon alfa-2a (40 KD) (pegasys) plus ribavirin (copegus) versus interferon alfa-2b Plus ribavirin as first treatment of chronic hepatitis C in the UK
    Lewis, GJ
    Green, J
    Patel, K
    Philips, Z
    VALUE IN HEALTH, 2004, 7 (06) : 763 - 764
  • [50] Treatment of patients with chronic hepatitis C with peginterferon alfa-2a (40KD) (Pegasys®) alone or in combination with ribavirin results in long-lasting sustained virological response.
    Swain, M
    Lai, MY
    Shiffmann, ML
    Cooksley, WGE
    Abergel, A
    Diago, M
    Brunda, M
    HEPATOLOGY, 2002, 36 (04) : 598A - 598A
12345